News

MTX325 shows promise in mouse model as Parkinson’s therapy

Mission Therapeutics’ experimental oral therapy MTX325, for Parkinson’s disease, spurred brain cells in mice to clear damaged mitochondria — the powerhouses of the cells — ultimately protecting them from death caused by toxic alpha-synuclein protein clumping. That’s according to the findings of a new study using a Parkinson’s…

Noninvasive way of deep brain stimulation to be tested in patients

A pilot trial into whether deep brain stimulation based on noninvasive neuromodulation of a lower leg nerve can safely and effectively ease symptoms of Parkinson’s disease and essential tremor is fully enrolled, Stimvia, its developer, announced. The 24 patients in the study (NCT06036368) will use the company’s…

Parkinson’s vaccine, UB-312, slows alpha-synuclein clumping in patients

UB-312, an experimental vaccine being developed for Parkinson’s disease by Vaxxinity, induced the production of antibodies targeting alpha-synuclein and slowed protein clumping in patients’ cerebrospinal fluid (CSF), the fluid that surrounds the brain and the spinal cord. The vaccine is designed to stimulate a patient’s immune system…

Compounds from marigold flowers show promise as treatment

Compounds extracted from marigold flowers may be useful in treating Parkinson’s disease, according to a study done in laboratory models. The study, “Active compounds from Calendula officinalis flowers act via PI3K and ERK signaling pathways to offer neuroprotective effects against Parkinson’s disease,” was published in Food…

6 Latin American countries asked to OK Inbrija for off periods

Biopas Laboratories has asked the regulatory agencies of six countries in Latin America to approve Inbrija for Parkinson’s disease off periods, according to Acorda Therapeutics, the therapy’s developer and Biopas’ partner. Inbrija is a self-administered, inhaled levodopa therapy developed to reduce periods when motor symptoms are…